AI
Tuesday, July 02, 2019 10:53:29 PM
$LAHO..stem cell..market compound annual growth..37 percent
..“There has been an increased demand to develop effective drugs for cardiology and degenerative disorders, for which there were no effective treatment plans before the advent of stem therapies. The discovery of possible cardiac stem cells uncovered new arenas to repair hearts injured due to acute myocardial infarction or coronary artery disease,”
https://www.dailyprogress.com/opinion/opinion-commentary-global-stem-cell-therapy-market-to-showcase-growth/article_aeabbd8e-0106-11e7-a193-db25ffa753ac.amp.html
Researchers are studying and developing approximately 19 product candidates for the treatment of cardiac disorders, with eight of them in Phase III, and six in Phase II.
.$20 billion in mergers and acquisitions in the cell and gene therapy space, or regenerative medicine, that year, according to the Alliance for Regenerative Medicine.
..FDA has "more than 800 active cell-based or directly administered gene therapy INDs on file."
https://www.spglobal.com/marketintelligence/en/news-insights/trending/nATYU0f9Kb7ki7MR_mlO-A2
Global Stem Cells Group Plans Bone Marrow Clinical Trials For Knee Osteoarthritis
https://biovaultfamily.com/health-hub/musculoskeletal-conditions/global-stem-cells-group-plans-bone-marrow-clinical-trials-for-knee-osteoarthritis/
https://investorshub.advfn.com/secure/post_reply.aspx?message_id=149714565
Global Stem Cells Group Subsidiary Adimarket to Launch Progenikine™ SVF Closed System
..Developed in conjunction with Patrick Pennie, Emcyte CEO, and Maritza Novas Director of Research and Development for Global Stem Cells Group, Progenikine fuses elements from Emcyte systems with the Global Stem cells Group SVF protocols.
https://stemcellinc.in/global-stem-cells-group-subsidiary-adimarket-to-launch-progenikine-svf-closed-system/
http://www.stemcellsgroup.com/magellan-autologous-platelet-separator/magellan_logo2/
$LAHO GSCG
..“There has been an increased demand to develop effective drugs for cardiology and degenerative disorders, for which there were no effective treatment plans before the advent of stem therapies. The discovery of possible cardiac stem cells uncovered new arenas to repair hearts injured due to acute myocardial infarction or coronary artery disease,”
https://www.dailyprogress.com/opinion/opinion-commentary-global-stem-cell-therapy-market-to-showcase-growth/article_aeabbd8e-0106-11e7-a193-db25ffa753ac.amp.html
Researchers are studying and developing approximately 19 product candidates for the treatment of cardiac disorders, with eight of them in Phase III, and six in Phase II.
.$20 billion in mergers and acquisitions in the cell and gene therapy space, or regenerative medicine, that year, according to the Alliance for Regenerative Medicine.
..FDA has "more than 800 active cell-based or directly administered gene therapy INDs on file."
https://www.spglobal.com/marketintelligence/en/news-insights/trending/nATYU0f9Kb7ki7MR_mlO-A2
Global Stem Cells Group Plans Bone Marrow Clinical Trials For Knee Osteoarthritis
https://biovaultfamily.com/health-hub/musculoskeletal-conditions/global-stem-cells-group-plans-bone-marrow-clinical-trials-for-knee-osteoarthritis/
https://investorshub.advfn.com/secure/post_reply.aspx?message_id=149714565
Global Stem Cells Group Subsidiary Adimarket to Launch Progenikine™ SVF Closed System
..Developed in conjunction with Patrick Pennie, Emcyte CEO, and Maritza Novas Director of Research and Development for Global Stem Cells Group, Progenikine fuses elements from Emcyte systems with the Global Stem cells Group SVF protocols.
https://stemcellinc.in/global-stem-cells-group-subsidiary-adimarket-to-launch-progenikine-svf-closed-system/
http://www.stemcellsgroup.com/magellan-autologous-platelet-separator/magellan_logo2/
$LAHO GSCG
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
